RHODA OLATAYO: Open Payments
NPI 1821706912 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,560 in 69 payments from 13 companies in 2025. Trend: 2023 $970 · 2024 $1,733 · 2025 $1,560
Food & beverage: $1,560
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $716 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $222 |
| Madrigal Pharmaceuticals | 4 | $110 |
| Janssen Biotech, Inc. | 4 | $107 |
| GENZYME CORPORATION | 3 | $104 |
| Aimmune Therapeutics, Inc. | 3 | $74 |
| Celltrion USA Inc. | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $46 |
| EVOKE PHARMA, INC. | 2 | $36 |
| Ipsen Biopharmaceuticals, Inc | 1 | $30 |
Products named: SKYRIZI, ENTYVIO, RINVOQ, CREON, LINZESS, REZDIFFRA, TREMFYA, DUPIXENT.
Industry payments across TX — which companies pay providers there.
